In the following video, Fool contributor Maxxwell Chatsko tells investors about pipeline developments from Merck (NYSE:MRK). The Food and Drug Administration will review Biologics License Applications, or BLAs, for two investigational allergy tablets in the first half of 2014. Investors awaiting the next big pipeline hit to help replace falling revenue from patent expirations throughout the portfolio should have their ears perked up on the news. 

How do these tablets work in the body? What is their revenue potential? Maxxwell explains just what it means for Merck and investors and answers one important question.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.